Strs Ohio Has $952,000 Holdings in STAAR Surgical (NASDAQ:STAA)

Strs Ohio grew its position in STAAR Surgical (NASDAQ:STAAGet Rating) by 4.7% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 13,500 shares of the medical instruments supplier’s stock after purchasing an additional 600 shares during the period. Strs Ohio’s holdings in STAAR Surgical were worth $952,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in STAA. China Universal Asset Management Co. Ltd. lifted its holdings in STAAR Surgical by 264.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 496 shares of the medical instruments supplier’s stock worth $35,000 after purchasing an additional 360 shares during the last quarter. Lazard Asset Management LLC boosted its position in STAAR Surgical by 131.1% during the first quarter. Lazard Asset Management LLC now owns 684 shares of the medical instruments supplier’s stock valued at $54,000 after acquiring an additional 388 shares during the last quarter. UBS Group AG grew its stake in STAAR Surgical by 130.7% during the second quarter. UBS Group AG now owns 805 shares of the medical instruments supplier’s stock worth $57,000 after purchasing an additional 456 shares during the period. Captrust Financial Advisors grew its holdings in STAAR Surgical by 348.4% in the second quarter. Captrust Financial Advisors now owns 825 shares of the medical instruments supplier’s stock worth $59,000 after purchasing an additional 641 shares during the period. Finally, Wipfli Financial Advisors LLC bought a new stake in STAAR Surgical in the 3rd quarter valued at about $79,000. 97.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at STAAR Surgical

In related news, major shareholder Broadwood Partners, L.P. bought 51,985 shares of the company’s stock in a transaction dated Tuesday, December 27th. The stock was bought at an average price of $47.91 per share, with a total value of $2,490,601.35. Following the transaction, the insider now owns 8,643,992 shares of the company’s stock, valued at $414,133,656.72. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. 2.60% of the stock is owned by company insiders.

STAAR Surgical Stock Up 3.1 %

STAA stock opened at $72.50 on Friday. The stock has a market cap of $3.50 billion, a price-to-earnings ratio of 95.40 and a beta of 1.05. The business has a fifty day moving average of $58.36 and a two-hundred day moving average of $73.16. STAAR Surgical has a 52-week low of $46.35 and a 52-week high of $112.27.

STAAR Surgical (NASDAQ:STAAGet Rating) last posted its earnings results on Wednesday, November 2nd. The medical instruments supplier reported $0.25 earnings per share for the quarter, topping the consensus estimate of $0.13 by $0.12. The firm had revenue of $76.05 million during the quarter, compared to analysts’ expectations of $74.95 million. STAAR Surgical had a return on equity of 15.13% and a net margin of 13.54%. The firm’s revenue was up 30.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.13 earnings per share. As a group, sell-side analysts anticipate that STAAR Surgical will post 0.83 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on STAA shares. Sidoti upgraded STAAR Surgical from a “neutral” rating to a “buy” rating in a research note on Monday, November 7th. Mizuho initiated coverage on shares of STAAR Surgical in a report on Wednesday, October 12th. They set a “buy” rating and a $85.00 target price on the stock. Stephens lowered their target price on shares of STAAR Surgical from $91.00 to $85.00 and set an “overweight” rating on the stock in a research note on Wednesday, December 28th. BTIG Research lowered their price objective on shares of STAAR Surgical from $80.00 to $67.00 and set a “buy” rating for the company in a report on Wednesday, December 28th. Finally, Needham & Company LLC dropped their price objective on STAAR Surgical from $110.00 to $83.00 and set a “buy” rating for the company in a research note on Thursday, November 3rd. Two research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $87.70.

STAAR Surgical Company Profile

(Get Rating)

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness.

Featured Stories

Institutional Ownership by Quarter for STAAR Surgical (NASDAQ:STAA)

Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.